Roman Trawicki - Zoetis President

ZTS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Mr. Roman Trawicki is Executive Vice President, President of Global Manufacturing and Supply of the Company
Age: 54  President Since 2015      
973 822-7000
Trawicki has served as our Executive Vice President and President, Global Manufacturing and Supply since May 2015. He joined Zoetis in January 2015 as President, Global Manufacturing and Supply. From 2009 to 2014, he was GE Healthcare?s General Manager of Global Supply Chain for Medical Diagnostics, where he focused on diagnostics, injectable contrast media and nuclear medicines.

Roman Trawicki Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Jay MarkowitzRegeneron Pharmaceuticals
Joseph LaRosaRegeneron Pharmaceuticals
John HendricksonPerrigo Company Plc
Christopher FenimoreRegeneron Pharmaceuticals
Michael StewartPerrigo Company Plc
Raghav ChariDr Reddys Laboratories Ltd
Charles MilsteinVertex Pharmaceuticals Incorpor
Alok SonigDr Reddys Laboratories Ltd
James DillardPerrigo Company Plc
Ronald JanishPerrigo Company Plc
Douglas BoothePerrigo Company Plc
Paul SilvaVertex Pharmaceuticals Incorpor
Saumen ChakrabortyDr Reddys Laboratories Ltd
Peter PowchikRegeneron Pharmaceuticals
Cartikeya ReddyDr Reddys Laboratories Ltd
J RamachandranDr Reddys Laboratories Ltd
Marion McCourtRegeneron Pharmaceuticals
Daniel PlewRegeneron Pharmaceuticals
Jeffrey NeedhamPerrigo Company Plc
Reshma KewalramaniVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drugs - Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Optimization Now


Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Also Currentnly Active

Purchased over 70 shares of
a day ago
Traded for 36.89
Purchased few shares of
a day ago
Traded for 163.21
Purchased over 70 shares of
a day ago
Traded for 36.89
See also Your Current Watchlist. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.